During the past quarter, Allogene Therapeutics ALLO saw the following analyst ratings:
|quickly||bit bullish||Moody||bit bearish||recession|
These 4 analysts have an average price target of $29.25 versus Allogen Therapeutics’ current price of $11.53, which is an upward move.
Below is a summary of how these 4 analysts rated Allogene Therapeutics over the last 3 months. The higher the number of bullish ratings, the more positive analysts rate the stock, and the higher the number of bearish ratings, the more negative analysts rate the stock.
This is an 11.43% increase from the current average price target of $26.25.
If you’re interested in following small-cap stock news and performance, you can start by following them here.
Analysts are experts in banking and financial systems, who typically produce reports for specific stocks or defined sectors. These people research a company’s financial statements, attend conference calls and meetings, and speak with relevant insiders to determine what is called an analyst rating for a stock. Typically, analysts rate each stock once a quarter.
Some analysts release their forecasts for metrics like growth forecasts, earnings, and sales to provide additional guidance with their ratings. When using analyst ratings, it is important to remember that stock and sector analysts are people too and are simply providing investors with their opinions.
This article was created by Benzinga’s Automated Content Engine and is editor-reviewed.